---
title: Find tests predicting disease progression
nct_id: NCT05266872
status: RECRUITING
sponsor: Luxembourg Institute of Health
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05266872"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05266872"
last_fetched: "2026-05-10T14:05:36.516Z"
source: "Parkinson's Pathways (curated)"
---
# Find tests predicting disease progression

**Goal (in five words):** Find tests predicting disease progression

**Official Title:** Biomaterial Collection for Neurodegenerative Disease Research (ND Collection)

**Trial ID:** [NCT05266872](https://clinicaltrials.gov/study/NCT05266872)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Luxembourg Institute of Health
- **Target Enrollment:** 1800 participants
- **Start Date:** 2014-12-19
- **Completion Date:** 2025-12-31
- **Conditions:** Parkinson Disease
- **Interventions:** Observational study with sample and data collection
- **Intervention Types:** OTHER

## Summary For Families

The goal is to create a large, well-characterized biobank of blood, spinal fluid, skin and other samples linked to clinical data so researchers can find biomarkers, understand what drives Parkinson's, and track disease progression. Participants give samples and health information, with procedures that can include blood draws, optional lumbar puncture for cerebrospinal fluid, and skin biopsies, so scientists can look for molecules or changes that predict diagnosis, course, or treatment response. People 18 and older with typical Parkinson's or atypical parkinsonism who can consent, or who have an authorized representative, can join, while those with active cancer, pregnancy, refusal to consent, or bleeding problems that make biopsies or lumbar puncture unsafe are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism)
* Subjects of all genders with a full capacity of consent
* Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement
* Subjects of at least 18 years of age at the time of inclusion

Exclusion Criteria:

* Refusal to sign the informed consent
* Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion
* Active cancer
* Pregnant women
* Underage subjects of less than 18 years of age
* Refusal to comply with mandatory sample collection
* For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.
```

## Locations (2)

- Centre Hospitalier de Luxembourg (CHL), "Parkinson's Research Clinic", Luxembourg, Luxembourg _(49.6098, 6.1327)_
  - Rejko KRÜGER — (CONTACT) — +35244114848 — rejko.krueger@uni.lu
- Clinical and Epidemiological Investigation Center (CIEC), Luxembourg, Luxembourg _(49.6098, 6.1327)_
  - Manon Gantenbein — (CONTACT) — +352 26970-807 — Manon.Gantenbein@lih.lu

## Central Contacts

- Rejko KRÜGER, Dr — (CONTACT) — +352 44 11 4848 — rejko.krueger@uni.lu
- Parkinson clinic — (CONTACT) — +352 44 11 4848 — parkinson@chl.lu

---

*Canonical: https://parkinsonspathways.com/trial/NCT05266872*  
*HTML version: https://parkinsonspathways.com/trial/NCT05266872*  
*Source data: https://clinicaltrials.gov/study/NCT05266872*